TNGX
Tango Therapeutics (TNGX) Q4 Loss Narrows to $0.29/Share vs $0.33 Estimate; Shares Surge 23%
Tango Therapeutics posts narrower-than-expected Q4 loss of $0.29/share vs $0.33 estimate; shares jump 23% on the biotech's results.
Tango Therapeutics Q4 FY25 Earnings Results
Financial Performance and Profitability Tango Therapeutics reported zero collaboration revenue for the fourth quarter of 2025, a decrease from $5.4…